At WCLC 2026, MedJ asks Prof. Paul A. Bunn Jr. how the field should think about treatment duration after adjuvant osimertinib, the potential role of antibody–drug conjugates (ADCs) in small cell lung cancer, and priorities for thoracic cancer research.
The interview also examines IASLC’s international, thoracic-cancer-focused role and the continuing challenges of prevention, screening and early detection.
Prof. Paul A. Bunn Jr. is Distinguished Professor of Medicine at the University of Colorado School of Medicine, Anschutz Medical Campus, and holds the James Dudley Endowed Chair in Cancer Research. Prof. Bunn is a Fellow of ASCO and a recipient of ASCO’s 2016 David A. Karnofsky Memorial Award.
Key highlights from this clip:
● Why IASLC’s international focus on thoracic cancers distinguishes it from broader oncology organizations.
● Why some patients may need treatment beyond three years after adjuvant osimertinib, and how circulating tumor DNA and other circulating markers could help guide treatment duration.
● Why less toxic alternatives to the five-day topotecan regimen are urgently needed in small cell lung cancer.
● How ADCs may contribute to the next generation of small cell lung cancer treatment.
● What important clinical-trial data from China means for global thoracic oncology.
● Why tobacco control, air-pollution research, screening, early detection and international collaboration remain priorities.
This video is intended for medical education and professional discussion.